Current Research in Medical Sciences
Babol Univesity of Medical Sciences
Wed, Feb 18, 2026
[Archive]
Volume 9, Issue 1 (4-2025)
CRMS 2025, 9(1): 32-43 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Jafarian E, Monadi M, Shirafkan H, Mehdinezhad H. Adding Baricitinib to the Standard Treatment in Severe COVID-19 Patients: A Retrospective Cohort Study. CRMS 2025; 9 (1) :32-43
URL: http://crms.mubabol.ac.ir/article-1-199-en.html
URL: http://crms.mubabol.ac.ir/article-1-199-en.html
Department of Internal Medicine, Babol University of Medical Sciences, Babol, Iran , h.mehdinezhad56@gmail.com
Abstract: (1070 Views)
Background: The severe form of coronavirus disease 2019 (COVID-19) is mainly marked by hyper inflammation and the associated multi-organ damage it causes. Baricitinib has been shown to have dual anti-inflammatory and antiviral effects. Our study aims to evaluate the effect of adding Baricitinib to the standard treatment on clinical and laboratory outcomes in patients with COVID-19 pneumonia.
Methods: In this retrospective cohort study conducted at three tertiary hospitals affiliated with Babol University of Medical Sciences, the medical records of 129 adult patients with severe COVID-19 pneumonia were reviewed. Patients were divided into two groups: one received standard treatment with remdesivir and corticosteroids, and the other received Baricitinib (4 mg daily for up to 14 days) in addition to the standard treatment. Outcomes included duration of hospital stay, 14- and 28-day mortality, arterial oxygen saturation, disease severity, invasive ventilation need, and ICU admission.
Results: Among the 129 patients (mean age 55.33 ± 14.88 years; 34.1% men), the Baricitinib group showed significantly lower disease severity at 14 days (p=0.02), reduced 14-day (0/66 vs 8/63, p=0.003) and 28-day mortality (1/66 vs 9/63, p=0.008), and greater arterial oxygen saturation improvement (p<0.001). The ICU and invasive ventilation duration did not differ between the two groups (p = 0.58 and p = 0.99, respectively).
Conclusion: This study found that adding Baricitinib to the standard treatment in severe COVID-19 pneumonia could reduce mortality and disease severity and improve arterial blood oxygen saturation compared to standard treatment only
Methods: In this retrospective cohort study conducted at three tertiary hospitals affiliated with Babol University of Medical Sciences, the medical records of 129 adult patients with severe COVID-19 pneumonia were reviewed. Patients were divided into two groups: one received standard treatment with remdesivir and corticosteroids, and the other received Baricitinib (4 mg daily for up to 14 days) in addition to the standard treatment. Outcomes included duration of hospital stay, 14- and 28-day mortality, arterial oxygen saturation, disease severity, invasive ventilation need, and ICU admission.
Results: Among the 129 patients (mean age 55.33 ± 14.88 years; 34.1% men), the Baricitinib group showed significantly lower disease severity at 14 days (p=0.02), reduced 14-day (0/66 vs 8/63, p=0.003) and 28-day mortality (1/66 vs 9/63, p=0.008), and greater arterial oxygen saturation improvement (p<0.001). The ICU and invasive ventilation duration did not differ between the two groups (p = 0.58 and p = 0.99, respectively).
Conclusion: This study found that adding Baricitinib to the standard treatment in severe COVID-19 pneumonia could reduce mortality and disease severity and improve arterial blood oxygen saturation compared to standard treatment only
Type of Study: Original Article |
Subject:
داخلی
Received: 2025/01/12 | Accepted: 2025/06/10 | Published: 2025/06/16
Received: 2025/01/12 | Accepted: 2025/06/10 | Published: 2025/06/16
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
